234 related articles for article (PubMed ID: 24201238)
1. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
2. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Takahashi S; Suzuki M; Uchiyama M
Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
[TBL] [Abstract][Full Text] [Related]
3. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
4. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
5. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Lee BH; Kim YK; Park SH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
[TBL] [Abstract][Full Text] [Related]
6. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
7. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
8. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1361-2. PubMed ID: 20647025
[No Abstract] [Full Text] [Related]
11. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
Garcia E; Robert M; Peris F; Nakamura H; Sato N; Terazawa Y
CNS Drugs; 2009; 23(7):615-25. PubMed ID: 19552488
[TBL] [Abstract][Full Text] [Related]
13. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
14. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Yuan HN; Wang CY; Sze CW; Tong Y; Tan QR; Feng XJ; Liu RM; Zhang JZ; Zhang YB; Zhang ZJ
J Clin Psychopharmacol; 2008 Jun; 28(3):264-370. PubMed ID: 18480682
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
[TBL] [Abstract][Full Text] [Related]
16. Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
Yu W; Lei L; Yu Y; Li Y; Shen Y; Li H
Hum Psychopharmacol; 2020 Jan; 35(1):e2717. PubMed ID: 31837240
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with blonanserin for drug-induced hyperprolactinemia in chronic schizophrenia patients: a six-month follow-up of two cases.
Kito S; Hasegawa T; Nakajima T; Koga Y; Hibi S; Tobe Y; Mochida M
J Neuropsychiatry Clin Neurosci; 2013; 25(3):E29-30. PubMed ID: 24026734
[No Abstract] [Full Text] [Related]
18. Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED; Keating GM
CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
[TBL] [Abstract][Full Text] [Related]
19. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study.
Lee MS; Song HC; An H; Yang J; Ko YH; Jung IK; Joe SH
Psychiatry Clin Neurosci; 2010 Feb; 64(1):19-27. PubMed ID: 19968833
[TBL] [Abstract][Full Text] [Related]
20. Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
Tenjin T; Miyamoto S; Miyake N; Ogino S; Kitajima R; Ojima K; Arai J; Teramoto H; Tsukahara S; Ito Y; Tadokoro M; Anai K; Funamoto Y; Kaneda Y; Sumiyoshi T; Yamaguchi N
Hum Psychopharmacol; 2012 Jan; 27(1):90-100. PubMed ID: 22278973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]